India pins hopes on locally-tested COVID-19 vaccines given Pfizer constraints


  • World
  • Tuesday, 17 Nov 2020

FILE PHOTO: A healthcare worker wearing personal protective equipment (PPE) collects a swab sample from a woman amidst the spread of the coronavirus disease (COVID-19), at a wholesale market, in the old quarters of Delhi, India, November 17, 2020. Picture taken with slow shutter speed. REUTERS/Adnan Abidi

NEW DELHI (Reuters) - India hopes five locally-tested vaccines will help it to control COVID-19, as those developed by Pfizer and Moderna may not be available to it in big quantities soon.

The five candidates include Russia's Sputnik-V whose "Phase-II going to Phase-III" trials in India will start next week in collaboration with Dr Reddy's Laboratories, Vinod Paul, the head of a committee advising the prime minister, said.

The other experimental vaccines are the one being developed by AstraZeneca and Oxford University which is being manufactured by the Serum Institute of India; Bharat Biotech and the Indian government's COVAXIN; Zydus Cadila's ZyCoV-D and lastly one being developed by Biological E. Ltd alongside Baylor College of Medicine and Dynavax Technologies Corp.

Paul told a news briefing that AstraZeneca vaccine's last-stage trials in India had gone well and had almost been completed. The country of 1.35 billion people has reported 8.87 million infections, second only to the United States, and 130,519 deaths as a result of COVID-19.

"We are very hopeful that we will be successful with the five vaccines," Paul said on Tuesday. "They are easy platforms, availability of doses is very high. They will be able to control our pandemic in terms of the numbers of doses required."

Paul said the government was also watching the progress of the Pfizer and Moderna vaccines, both of which have said interim results of last-stage trials of their candidates showed that they were more than 90% effective.

Unlike Pfizer's vaccine which must be kept at minus 70 degrees Celsius or below, Moderna's can be stored at normal fridge temperatures, making it more suited for poorer countries such as India where cold chains are limited.

"This obviously will be a very big hindrance to scale up the vaccine," Paul said of Pfizer's, adding that if India finds itself needing to do so it will pursue this option.

"If we are required to form our strategy on this particular vaccine, then we will proceed with it. Though, even if we get it, we will get it in a few months only. But talks are ongoing."

(Reporting by Krishna N. Das; Editing by Alexander Smith)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!
   

Next In World

Apple’s Pay Later service may be delayed until next year
Iran says U.S. trying to violate sovereignty over unrest, warns of response
Ukraine's Zelenskiy doesn't think Putin is bluffing over nuclear arms
More Russians travelled to Finland during weekend, border data shows
Ukraine's Zelenskiy says two more burial sites found in liberated Izium
A startup has put electrodes in a patient’s skull to treat depression
U.N. food agency says debris from drone strike hit truck in northern Ethiopia
EU crisis response meeting to discuss developments in Russia
U.S. VP Harris, Japan PM Kishida to discuss Taiwan security issue -US administration official
Political reaction to Italian election outcome

Others Also Read